Sanofi announced that its atopic dermatitis candidate, amlitelimab, met primary endpoints in a phase III clinical trial; however, the data fell short of industry and investor expectations relative to earlier phase 2 results and comparable products in development. The anti-OX40L antibody showed improvement in skin clearance and disease severity against placebo, yet concerns persist about its competitive positioning. This outcome adds to ongoing challenges for Sanofi’s immunology portfolio and prompts re-evaluation of its therapeutic strategy in dermatology.